This is a routine partnership announcement with no financial impact. Monitor HLP003 Phase 3 data readouts and regulatory milestones for stock-moving catalysts. The executive order provides tailwinds but does not change near-term fundamentals.
Price Chart
Executive Summary
Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003 program in major depressive disorder, aligning with a recent executive order on veteran mental health. The partnership is a non-financial clinical trial support agreement with no disclosed deal value, representing a routine operational update for a clinical-stage biotech.
Key Facts
- Collaboration with TARA Mind to support recruitment for HLP003 Phase 3 program in MDD
- HLP003 has FDA Breakthrough Therapy Designation
- Partnership aligns with April 18, 2026 Executive Order on mental health treatments
- No financial terms or deal value disclosed
- HLP004 is in Phase 2 for generalized anxiety disorder
Financial Impact
No financial terms disclosed; collaboration is operational in nature
Risk Factors
- No financial commitment from TARA Mind — partnership may not materially accelerate enrollment
- Phase 3 clinical trial risks (efficacy, safety, regulatory)
- Company has no approved products and relies on future financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285629 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.20 (+0.89%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.20 (−6.03%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.20 (−2.86%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.20 (−2.86%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.20 (−2.86%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.20 (−2.86%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.20 (−2.86%) |
Oct 15, 2026 12d ago | 6-K | $11.05 | awaiting T+20 | — | $10.20 (−7.69%) |
Oct 15, 2026 12d ago | Press Release | $11.05 | awaiting T+20 | — | $10.20 (−7.69%) |
Oct 8, 2026 19d ago | 6-K | $10.72 | awaiting T+20 | — | $10.20 (−4.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers